ClinConnect ClinConnect Logo
Search / Trial NCT04143503

Observational Cohort Study on the Use of Parenteral Nutrition and Clinical Outcomes in Adult Critically Ill Patients

Launched by FRESENIUS KABI · Oct 28, 2019

Trial Information

Current as of August 02, 2025

Completed

Keywords

Icu Parenteral Nutrition Enteral Nutrition Energy Intake Protein Intake

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age ≥18 years and ≤95 years, male or female
  • 2. Hospitalised in a medical, surgical, or trauma ICU for at least five consecutive calendar days and either admitted to the ICU during the predefined screening month or admitted to the ICU maximally 4 days before start of the screening month
  • 3. BMI ≥18.5 kg/m2 and ≤45 kg/m2
  • 4. Written informed consent or requirements of local/national ethical committee
  • Exclusion Criteria:
  • 1. Burn injury
  • 2. Pre-existing neuromuscular or psychiatric disorders that preclude proper assessment of functional status
  • 3. Severe hypoxic brain injury or severe neurological diagnosis (e.g. meningitis, encephalitis, brain trauma, spinal cord injury) at the time of ICU admission that precludes proper assessment of functional status
  • 4. Receiving home parenteral nutrition at the time of ICU admission (e.g. due to short bowel syndrome)
  • 5. Receiving home enteral nutrition (tube feeding) at the time of ICU admission
  • 6. Chronic invasive or chronic non-invasive ventilatory support before ICU admission
  • 7. Patients with a legal representative in place before ICU admission
  • 8. Admission to the ICU for palliative care
  • 9. Previous participation in this study (if the screening month is repeated and a patient is re-admitted to the ICU during the repeated screening month, only ICU data collected for that patient during the original screening month will be included)
  • 10. Concurrent enrolment in a nutrition-related interventional study at the time of screening

About Fresenius Kabi

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technology, with a strong focus on the areas of intravenous (IV) therapies, infusion devices, and clinical nutrition. With a commitment to enhancing patient care, Fresenius Kabi conducts innovative clinical trials to develop high-quality pharmaceuticals and medical devices that address unmet medical needs. The company leverages its extensive expertise in drug formulation and delivery systems to advance therapeutic solutions across various clinical indications, ensuring safety and efficacy in diverse patient populations. Through its robust research and development initiatives, Fresenius Kabi aims to contribute significantly to the healthcare landscape and improve outcomes for patients worldwide.

Locations

Valenciennes, , France

Milano, , Italy

Stuttgart, , Germany

Barcelona, , Spain

Marseille, , France

Vienna, , Austria

Brussels, , Belgium

Lleida, , Spain

Edegem, , Belgium

Suresnes, , France

Gent, , Belgium

Leipzig, , Germany

Brussels, , Belgium

Suresnes, , France

Charleroi, , Belgium

Białystok, , Poland

Valladolid, , Spain

Liverpool, , United Kingdom

Burgos, , Spain

Liverpool, , United Kingdom

Madrid, , Spain

Munich, , Germany

Clermont Ferrand, , France

Angers, , France

Bochum, , Germany

Veszprém, , Hungary

Prague, , Czechia

Palma De Mallorca, , Spain

Besançon, , France

Székesfehérvár, , Hungary

Vigo, , Spain

Nyíregyháza, , Hungary

ústí Nad Labem, , Czechia

Arlon, , Belgium

Brussels, , Belgium

Ottignies, , Belgium

Tournai, , Belgium

Brno, , Czechia

Brno, , Czechia

Brno, , Czechia

Hradec Králové, , Czechia

Hradec Králové, , Czechia

Hradec Králové, , Czechia

Olomouc, , Czechia

Pardubice, , Czechia

Plzen, , Czechia

Plzen, , Czechia

Prague, , Czechia

Brest, , France

Caen, , France

Chambray Lès Tours, , France

La Tronche, , France

Lyon, , France

Saint étienne, , France

Vandœuvre Lès Nancy, , France

Berlin, , Germany

Berlin, , Germany

Hannover, , Germany

Kiel, , Germany

Wetzlar, , Germany

Budapest, , Hungary

Budapest, , Hungary

Debrecen, , Hungary

Foggia, , Italy

Nocera Inferiore, , Italy

Ravenna, , Italy

Rimini, , Italy

Bydgoszcz, , Poland

Katowice, , Poland

Kraków, , Poland

Opole, , Poland

Poznań, , Poland

Girona, , Spain

Madrid, , Spain

Valencia, , Spain

Stockholm, , Sweden

London, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Michael Hiesmayr, Prof. MD

Principal Investigator

Medical University of Vienna

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials